Especially for indications with significant TATs, such as Trastuzumab Emtansine and Trastuzumab Deruxtecan targeting ERBB2, the prognosis and quality of life of ERBB2-positive breast cancer patients have been improved (Díaz-Rodríguez et al., 2021). The gene discussed is ERBB2; the disease is breast carcinoma.